8-K: Summit Therapeutics Unveils Strong Ivonescimab Trial Data

Summit Therapeutics announced positive Phase III clinical trial results for ivonescimab in NSCLC and initiated a new global Phase III study in colorectal cancer, alongside its Q3 2025 financial report.

Summary

• Summit plans to submit a Biologics License Application (BLA) for ivonescimab plus chemotherapy in Q4 2025 based on HARMONi trial results for EGFR-mutated NSCLC.
• The HARMONi trial demonstrated a statistically significant improvement in progression-free survival (PFS) with a Hazard Ratio (HR) of 0.52 (95% CI: 0.41 – 0.66; p<0.00001); median PFS was 6.8 months for ivonescimab plus chemotherapy versus 4.4 months for chemotherapy alone.
• Overall Survival (OS) in HARMONi showed a positive trend but did not achieve statistical significance in the primary analysis (HR=0.79; 95% CI: 0.62 – 1.01; p=0.057); median OS was 16.8 months versus 14.0 months.
• The Akeso-sponsored HARMONi-6 trial in China for squamous NSCLC showed ivonescimab plus chemotherapy reduced the risk of disease progression or death by 40% compared to tislelizumab plus chemotherapy.
• In HARMONi-6, median PFS was 11.14 months for ivonescimab plus chemotherapy versus 6.90 months for tislelizumab plus chemotherapy (HR=0.60; 95% CI: 0.46, 0.78; p<0.0001).
• Summit expanded its Phase III development program with HARMONi-GI3, a new global study in first-line unresectable metastatic colorectal cancer (CRC), aiming to enroll 600 patients.
• The HARMONi-3 global Phase III study protocol was amended to split statistical analyses by histology (squamous and non-squamous NSCLC), requiring enrollment of 600 squamous and 1,000 non-squamous patients.
• Q3 2025 GAAP net loss was $231.8 million, or $(0.31) per basic and diluted share, compared to $56.3 million, or $(0.08) per basic and diluted share, for Q3 2024.
• Cash and cash equivalents and short-term investments were $238.6 million at September 30, 2025, a decrease from $412.3 million at December 31, 2024.

Sentiment

Score: 8

Explanation: The filing presents very strong positive clinical data for ivonescimab in multiple NSCLC settings, including a head-to-head win against a PD-1 inhibitor plus chemotherapy, and plans for a BLA submission. The expansion into colorectal cancer also indicates strong pipeline potential. However, the lack of statistically significant overall survival in the primary HARMONi analysis and substantial increase in operating expenses and net loss, coupled with a significant reduction in cash, introduce financial and regulatory uncertainties.

Positives

• Statistically significant improvement in PFS in the HARMONi trial (HR=0.52, p<0.00001) for EGFRm NSCLC, which is believed to be clinically meaningful.
• Consistent PFS benefit observed across Asian and Western sub-populations in the HARMONi trial.
• Positive trend in OS observed in HARMONi, with an improved nominal p-value in longer-term western patient follow-up (HR=0.78, nominal p=0.0332).
• HARMONi-6 showed ivonescimab plus chemotherapy reduced disease progression or death by 40% compared to tislelizumab plus chemotherapy in squamous NSCLC (HR=0.60, p<0.0001).
• HARMONi-6 demonstrated higher Overall Response Rate (ORR) (75.9% vs. 66.5%) and longer Duration of Response (DoR) (11.20 months vs. 8.38 months) for the ivonescimab arm.
• Ivonescimab's safety profile was manageable and consistent with previous studies in both HARMONi and HARMONi-6.
• Expansion of the ivonescimab clinical development program into first-line metastatic CRC with the HARMONi-GI3 study, addressing a high unmet need.
• Ivonescimab is the first known regimen to achieve a clinically meaningful benefit over a PD-(L)1 inhibitor combined with chemotherapy in a head-to-head Phase III trial in 1L NSCLC.
• Ivonescimab received Fast Track designation from the US FDA for the HARMONi clinical trial setting.
• Over 3,000 patients have been treated with ivonescimab in clinical studies globally, and over 40,000 in a commercial setting in China.

Negatives

• The HARMONi trial did not achieve a statistically significant OS benefit in the primary analysis (p=0.057), which the FDA noted is necessary to support marketing authorization in this setting.
• GAAP operating expenses significantly increased to $234.2 million in Q3 2025 from $58.4 million in Q3 2024, primarily due to a $111.4 million increase in stock-based compensation expense.
• GAAP net loss widened to $231.8 million in Q3 2025 from $56.3 million in Q3 2024.
• Cash and cash equivalents and short-term investments decreased from $412.3 million at December 31, 2024, to $238.6 million at September 30, 2025.
• Higher incidence of Grade 3 or higher possibly VEGF-related adverse events in the ivonescimab arm (7.5%) compared to the tislelizumab arm (2.3%) in HARMONi-6, including Grade 3 or higher hemorrhage events in five patients versus two patients.

Risks

• The company's ability to sell shares of common stock under the At-The-Market (ATM) Program is subject to market conditions.
• General economic, industry, or political conditions, including geopolitical developments, domestic and foreign trade policies, and monetary policies, could impact operations.
• The outcome of discussions with regulatory authorities, including the Food and Drug Administration, regarding marketing approvals, especially concerning the need for a statistically significant overall survival benefit.
• Uncertainties inherent in the initiation of future clinical trials, including the availability and timing of data, and the ultimate success of such trials.
• Whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials or preclinical studies will be indicative of the results of later clinical trials.
• Availability of funding sufficient for foreseeable and unforeseeable operating expenses and capital expenditure requirements.
• Any change to ongoing trials could cause delays, affect future expenses, and add uncertainty to commercialization efforts, as well as affect the likelihood of successful completion of clinical development.
• Historical risks of toxicity, including hemorrhage and other life-threatening, bleeding-related complications, associated with VEGF-A monoclonal antibodies in squamous NSCLC.

Future Outlook

Summit plans to submit a Biologics License Application (BLA) for ivonescimab plus chemotherapy in Q4 2025 for EGFR-mutated NSCLC. The company intends to expand its ivonescimab clinical development program with an additional set of Phase III clinical studies, with details to be provided in Q1 2026. HARMONi-GI3 clinical trial sites are planned to begin activating in the United States prior to the end of 2025. HARMONi-3 squamous cohort enrollment is expected to complete in H1 2026, with PFS data readout in H2 2026, and non-squamous cohort enrollment expected to complete in H2 2026, with PFS data readout in H1 2027. Clinical trials with the Revolution Medicines collaboration are expected to begin in early 2026. Overall survival data for HARMONi-6 is not yet mature and will be evaluated in the future.

Management Comments

• "Based on the results of the HARMONi clinical trial, we plan to submit a Biologics License Application (BLA) in order to seek approval for ivonescimab plus chemotherapy for this proposed indication."
• "We believe that the safety and efficacy data generated in the HARMONi study demonstrates that patients suffering from epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) in this setting can benefit from the ivonescimab regimen despite the lack of a statistically significant showing on overall survival."
• "Microsatellite stable colorectal cancer represents a global unmet need whereby ivonescimab has the potential to bring the benefits of immunotherapy to solid tumors where PD-1 monoclonal antibodies have not been able to successfully improve upon existing standards of care." (Robert W. Duggan and Dr. Maky Zanganeh, Co-Chief Executive Officers)
• "We are thrilled by the potential of ivonescimab to make a significant difference to these patients with few front-line options available today." (Robert W. Duggan and Dr. Maky Zanganeh, Co-Chief Executive Officers)
• "The novel mechanism of action of ivonescimab may allow for an improved clinical profile and longer duration of therapy, which help improve outcomes – this distinguishes ivonescimab from other PD-1 monoclonal antibodies and PD-(L)1 plus VEGF treatments administered separately." (Dr. Maky Zanganeh, Co-Chief Executive Officer and President)
• "No more striking is this result than in squamous NSCLC where the benefit of anti-VEGF therapy has been largely unrealized. Combined with the improved benefit in patients across all levels of PD-L1 expression, implying a true improvement in the immunotherapy activity, this study of ivonescimab in combination with chemotherapy provides rich context as to the potential benefit of ivonescimab across solid tumors, reaffirming its incredible potential to help a wide variety of patients suffering from cancer." (Dr. Maky Zanganeh)
• "HARMONi-6 is yet another meaningful milestone for ivonescimab, Team Summit, and our partners at Akeso, and most importantly, continues to advance a potential treatment option for patients living with difficult-to-treat cancers." (Robert W. Duggan, Chairman and Co-Chief Executive Officer)

Industry Context

Ivonescimab, a novel bispecific antibody combining PD-1 blockade with anti-angiogenesis (VEGF blockade), aims to offer a differentiated approach to cancer treatment. The HARMONi-6 results are particularly impactful as it marks the first known Phase III trial in advanced NSCLC to demonstrate a statistically significant and clinically meaningful improvement over a PD-(L)1 inhibitor therapy combined with chemotherapy in a head-to-head setting. This is significant given the historical challenges and toxicity risks associated with VEGF-A monoclonal antibodies in squamous NSCLC. The expansion into first-line metastatic MSS CRC addresses a substantial unmet medical need, as current PD-1 inhibitors have largely failed in this patient population, with anti-VEGF therapy plus chemotherapy being the standard of care. The HARMONi trial's focus on EGFR-mutated NSCLC patients who have progressed after 3rd generation EGFR TKI also targets a high unmet need with limited approved options in Western territories.

Comparison to Industry Standards

• **HARMONi (EGFRm NSCLC after TKI)**: Ivonescimab + chemotherapy achieved a median PFS of 6.8 months (HR 0.52) compared to chemotherapy alone (median PFS 4.4 months). This addresses a setting with limited approved options and no FDA-approved regimens currently demonstrating a statistically significant OS benefit. The results are consistent with the single-region HARMONi-A study, which demonstrated an OS HR of 0.80 at 52% data maturity in a similar patient population.
• **HARMONi-6 (1L Squamous NSCLC)**: Ivonescimab + chemotherapy achieved a median PFS of 11.14 months (HR 0.60) compared to tislelizumab + chemotherapy (median PFS 6.90 months). This is the first known Phase III trial in NSCLC to show significant improvement over PD-(L)1 inhibitor therapy combined with chemotherapy in a head-to-head setting.
• **Comparison to KEYNOTE-407 (Pembrolizumab + Chemo in 1L Squamous NSCLC)**: The median PFS for the PD-1 + Chemo arm in KEYNOTE-407 was 6.4 months (HR=0.56 vs. Chemo alone). Ivonescimab's 11.14 months PFS in HARMONi-6 is substantially higher, indicating a potentially superior efficacy profile, although this was not a direct head-to-head comparison against pembrolizumab.
• **Comparison to RATIONALE-307 (Tislelizumab + Chemo in 1L Squamous NSCLC)**: The median PFS for the Tislelizumab + Chemo arm in RATIONALE-307 was 7.6 months (HR=0.52 vs. Chemo alone). Ivonescimab's 11.14 months PFS in HARMONi-6, in a direct head-to-head comparison against tislelizumab + chemotherapy, demonstrates a significant improvement.
• **HARMONi-GI3 (1L Unresectable Metastatic CRC)**: Ivonescimab + chemotherapy will be compared to bevacizumab + chemotherapy, which is the current standard of care for many patients with first-line metastatic MSS CRC. This is a setting where monoclonal PD-1 inhibitors (e.g., pembrolizumab, nivolumab) have historically failed to show clinically meaningful benefit. Akeso's Phase II data (AK112-206) showed an ORR of 81.8% and DCR of 100% with ivonescimab + FOLFOXIRI, providing encouraging preliminary results for this difficult-to-treat population.

Stakeholder Impact

• **Shareholders**: Potential for increased value due to positive clinical trial results and BLA submission plans, but also risk from significant cash burn and the lack of statistically significant OS in the HARMONi primary analysis.
• **Patients**: New, potentially more effective treatment options for advanced NSCLC and metastatic CRC, addressing high unmet medical needs.
• **Employees**: Continued and expanded development programs suggest stability and growth opportunities within the company.
• **Regulatory Authorities**: Will review the BLA submission for ivonescimab, with the FDA having noted the need for a statistically significant OS benefit in the HARMONi setting.
• **Partners (Akeso, Revolution Medicines)**: Strengthened collaboration and validation of ivonescimab's unique mechanism of action and broad potential.

Next Steps

• Submit a Biologics License Application (BLA) for ivonescimab plus chemotherapy in Q4 2025 for EGFR-mutated NSCLC.
• Provide additional details on new Phase III clinical studies in Q1 2026.
• Begin activating clinical trial sites for HARMONi-GI3 in the United States prior to the end of 2025.
• Complete enrollment in the HARMONi-3 squamous cohort in H1 2026.
• Reach the prespecified number of events for the HARMONi-3 squamous cohort PFS analysis in H2 2026.
• Conduct an interim OS analysis for the HARMONi-3 squamous cohort at a similar time (H2 2026).
• Complete enrollment in the HARMONi-3 non-squamous cohort in H2 2026.
• Reach the prespecified number of events for the HARMONi-3 non-squamous cohort PFS analysis in H1 2027.
• Conduct an interim OS analysis for the HARMONi-3 non-squamous cohort based on prespecified events.
• Begin clinical trials associated with the Revolution Medicines collaboration in early 2026.
• Evaluate overall survival data for HARMONi-6 in the future.

Key Dates

Recommendation

The clinical trial results for ivonescimab, particularly the HARMONi-6 head-to-head data showing superior PFS against a PD-1 inhibitor plus chemotherapy in 1L squamous NSCLC, are exceptionally strong and represent a potential paradigm shift in treatment. The planned BLA submission for EGFRm NSCLC, despite the lack of statistically significant OS in the primary analysis, is a bold move supported by consistent PFS and positive OS trends in Western patients, indicating management's confidence and a high unmet need. The expansion into colorectal cancer further diversifies the pipeline with promising early data. While the increased operating expenses and cash burn are notable, they reflect significant investment in a rapidly advancing and highly promising asset. The potential for ivonescimab to become a new standard of care in multiple oncology indications outweighs the current financial outflows and regulatory hurdles, making it a compelling long-term investment. The unique bispecific mechanism and demonstrated efficacy across various PD-L1 expressions suggest broad applicability and strong commercial potential.

Keywords

Ivonescimab, NSCLC, Colorectal Cancer, Squamous Non-Small Cell Lung Cancer, EGFR-mutated NSCLC, Bispecific Antibody, PD-1 Inhibitor, VEGF Blocker, HARMONi, HARMONi-6, HARMONi-3, HARMONi-GI3, Clinical Trial, Phase III, Biologics License Application, Oncology, Biopharmaceutical, Summit Therapeutics, Akeso, Progression-Free Survival, Overall Survival, FDA Fast Track